澳大利亚可能很快会补贴像Ozempic和Wegovy这样的减肥药品, Australia may soon subsidize weight loss drugs like Ozempic and Wegovy, expanding access beyond diabetes patients.

澳大利亚可能很快通过其药品福利计划,向Ozempic和Wegovy等减重药品提供补贴,从而可能降低使用者的费用。 Australia may soon offer subsidized access to weight loss drugs like Ozempic and Wegovy through its Pharmaceutical Benefits Scheme, potentially lowering costs for users. 卫生部长Mark Butler证实政府正在评估Novo Nordisk的投标, 以包括Wegovy, 预计2026年初会提供专家意见。 Health Minister Mark Butler confirmed the government is evaluating a bid by Novo Nordisk to include Wegovy, with expert advice expected early in 2026. 目前,这些GLP-1药物仅为2型糖尿病提供补贴,大约50万澳大利亚人每月私下支付200至600美元。 Currently, these GLP-1 drugs are only subsidized for type 2 diabetes, leaving around half a million Australians paying privately between $200 and $600 monthly. 治疗物品管理局对可能与自杀想法有关联以及口服避孕药与一些GLP-1药物的效用降低表示关切。 Concerns have been raised by the Therapeutic Goods Administration about possible links to suicidal thoughts and reduced effectiveness of oral contraceptives with some GLP-1 drugs. 政府的目标是在更广泛准入与安全和公平之间取得平衡。 The government aims to balance broader access with safety and equity.